Loading
A phase 3 trial of Talimogene laherparepvec and Pembrolizumab in Melanoma, run by Amgen, recorded as terminated on the registry.
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma is a phase 3 interventional study registered as NCT02263508 by Amgen, with 713 participants recorded, started 2014-12-08 and due to reach its primary completion in 2021-03-11. Interventions recorded: Talimogene Laherparepvec, Pembrolizumab, Placebo. Conditions recorded: Melanoma.
Linked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
713 enrolled.
95% CI 5.72 to 13.54; Figures from the ClinicalTrials.gov results section (first posted 2022-05-16), not from a publication · 95% CI 10.25 to 22.11
Source95% CI 38.4 to 81.9; Figures from the ClinicalTrials.gov results section (first posted 2022-05-16), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Phase 3: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessed Using Modified RECIST 1.1primary | Phase 3: Placebo + Pembrolizumab | 346 | 8.5 months | 0.86 (0.71 to 1.04) | 0.13 | link |
| Phase 3: Talimogene Laherparepvec + Pembrolizumab | 346 | 14.3 months | ||||
| Phase 1b: Objective Response Rate (ORR) | Phase 1b: Talimogene Laherparepvec + Pembrolizumab | 21 | 61.9% | - | - | link |
Shares Talimogene laherparepvec, Amgen, Melanoma and the tag pipeline.
Shares Talimogene laherparepvec, Amgen, Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.